Project 2018-01409
2018-01409
MX39795 CUPISCO: A PHASE II, RANDOMIZED, ACTIVE-CONTROLLED, MULTI-CENTER STUDY COMPARING THE EFFICACY AND SAFETY OF TARGETED THERAPY OR CANCER IMMUNOTHERAPY GUIDED BY GENOMIC PROFILING VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY SITE WHO HAVE RECEIVED THREE CYCLES OF PLATINUM DOUBLET CHEMOTHERAPY
multicentric
PD Dr. med. Benjamin Kasenda
Universitätsspital Basel, Klinik für Onkologie, 4031 Basel
Universitätsspital Zürich, Klinik für Onkologie, Zürich Kantonsspital Graubünden, Chur
clinical trial
phase 2
C
Ethikkommission Nordwest- und Zentralschweiz EKNZ
Kantonale Ethikkommission Zürich
22.10.2018
Roche Pharma (Schweiz) AG
Study has ended
drugs
|